For topical beta-blocker patients at risk for preservative toxicity, why add insult to injury?
- In a large clinical study in which patients were switched from a preserved to a preservative-free beta blocker, there was significant improvement in signs and symptoms of preservative toxicity on the ocular surface.1
- A significant reduction (p<0.0001) in all ocular signs and symptoms, especially in pain and discomfort, was seen in patients who were switched to a preservative-free formulation.1
Ocular symptoms at visits 1 and 2 in glaucoma patients switched from a preserved to a preservative-free topical glaucoma medication (n=3149)
• Help increase satisfaction for your patients who are discomforted by preservative toxicity
• Mitigate the preservative impact for your patients who may already have signs of ocular
surface disease (OSD) in one or both eyes
INDICATIONS AND USAGE
Preservative-free TIMOPTIC® in OCUDOSE® is indicated in the treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma. Preservative-free TIMOPTIC® in OCUDOSE® may be used when a patient is sensitive to the preservative in Timoptic (timolol maleate ophthalmic solution), benzalkonium chloride, or when use of a preservative-free topical medication is advisable.
IMPORTANT SAFETY INFORMATION
Timoptic is contraindicated in patients with: bronchial asthma; a history of bronchial asthma; severe chronic obstructive pulmonary disease; sinus bradycardia; second or third degree atrioventricular block; overt cardiac failure; cardiogenic shock; hypersensitivity to any component of this product.
This drug is absorbed systemically. The same adverse reactions found with systemic administration of beta-adrenergic blocking agents may occur with topical administration. Severe respiratory or cardiac reactions, including death, have been reported following systemic or ophthalmic administration of timolol maleate. Timoptic should be used with caution in patients with cerebrovascular insufficiency.
The most frequently reported adverse experiences have been burning and stinging upon instillation.
Please see full Prescribing Information by clicking on the link above.
References: 1. Jaenen N, Baudouin C, Pouliquen P, Manni G, Figueiredo A, Zeyen T. Ocular symptoms and signs with preserved and preservative-free glaucoma medications. Eur J Ophthalmol. 2007;17(3):341-349.